A novel multiplex RNAi therapy simultaneously targets Hif1a and Hif2a to defy retinal degeneration in two models of AMD
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2025.09.044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Lynn J A Ebner und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Z…. Hauptthemen laut MEDLINE: Macular Degeneration, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit, RNA Interference. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, University of Zurich, Swiss National Science Foundation.
Abstract (Originalsprache)
Age-related tissue changes lead to reduced oxygen delivery to photoreceptors and the retinal pigment epithelium (RPE) and contribute to the pathology of age-related macular degeneration (AMD). The implication of hypoxia-inducible factors (HIFs) in this process makes them good candidates as therapeutic targets for AMD. We developed a multiplex dual-acting therapy utilizing the shRNAmir system, delivered by a single adeno-associated virus, that reduces mRNA levels of Hif1a in photoreceptors and Hif2a in the RPE. This RNA interference (RNAi)-based strategy demonstrated a strong therapeutic effect, potently preserving photoreceptors and the RPE in two models of pseudo- and true hypoxia up to 61 weeks post-injection. The efficacy of our dual-acting virus proved superior to single-acting viruses targeting only Hif1a in photoreceptors or Hif2a in the RPE. By targeting a common, conserved disease pathway, this gene-agnostic RNAi therapy shows significant potential to protect tissues from chronic hypoxic insults in complex diseases such as AMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland.
- Department of Pediatrics, Powell Gene Therapy Center, University of Florida, Gainesville, FL 32601, USA.
- Department of Ophthalmology, University Hospital Zurich, 8091 Zurich, Switzerland.
- Department of Pediatrics, Division of Cellular and Molecular Therapy, University of Florida, Gainesville, FL 32610, USA.
- Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland. Electronic address: marijana.samardzija@usz.uzh.ch.
Förderung
- NEI NIH HHS
- University of Zurich
- Swiss National Science Foundation
Zitieren
APA
Ebner, L. J. A., Imsand, C., Karademir, D., Peters, F., Kiessling, E., Fottner, A., Matter, C., Fajardo, D. S., Merolla, L., Wögenstein, G. M., Tsioti, I., Govers, L. P., Blaser, F., Meneau, I., Boye, S. L., Boye, S. E., Grimm, C., & Samardzija, M. (2026). A novel multiplex RNAi therapy simultaneously targets Hif1a and Hif2a to defy retinal degeneration in two models of AMD. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.09.044
Vancouver
Ebner LJA, Imsand C, Karademir D, Peters F, Kiessling E, Fottner A, et al. A novel multiplex RNAi therapy simultaneously targets Hif1a and Hif2a to defy retinal degeneration in two models of AMD. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2025.09.044
BibTeX
@article{Ebner2026,
author = {Ebner, Lynn J A and Imsand, Cornelia and Karademir, Duygu and Peters, Florian and Kiessling, Eva and Fottner, Antonia and Matter, Claudia and Fajardo, Diego S and Merolla, Luca and Wögenstein, Gabriele M and Tsioti, Ioanna and Govers, Larissa P and Blaser, Frank and Meneau, Isabelle and Boye, Sanford L and Boye, Shannon E and Grimm, Christian and Samardzija, Marijana},
title = {A novel multiplex RNAi therapy simultaneously targets Hif1a and Hif2a to defy retinal degeneration in two models of AMD},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2025.09.044}
}
EUVIMED